| Product No | EMEA/H/C/003898 |
|---|---|
| Brand Name | Briviact (in Italy: Nubriveo) |
| Nonproprietary Name | brivaracetam |
| API | Brivaracetam |
| ATC Code | N03AX23 |
| Indications | Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. |
| Orphan Drug | no |
| Generics | no |
| Marketing Authorization Holder | UCB Pharma SA |
| Status | Authorised(授权) |
| Authorization Date | 2016-01-13 |
| Version | 21 |
| Condition Approval | no |
| Exceptions | no |
| Biosimilar | no |
| Details | 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息) |
Extended Information